# EDGAR Filing Document

**Accession Number:** 0001156375
**File Stem:** 0001156375-25-000199
**Filing Date:** 2025-9
**Character Count:** 20148
**Document Hash:** 33042a67beacc3a503d79d3740a1c225
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001156375-25-000199.hdr.sgml**: 20260702

**ACCESSION NUMBER**: 0001156375-25-000199

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250925

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CME GROUP INC.
- **CENTRAL INDEX KEY:** 0001156375
- **STANDARD INDUSTRIAL CLASSIFICATION:** SECURITY & COMMODITY BROKERS, DEALERS, EXCHANGES & SERVICES [6200]
- **ORGANIZATION NAME:** 09 Crypto Assets
- **EIN:** 364459170
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 20 S. WACKER DR.
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60606
- **BUSINESS PHONE:** 3129301000

**MAIL ADDRESS:**
- **STREET 1:** 20 S. WACKER DR.
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60606

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CHICAGO MERCANTILE EXCHANGE HOLDINGS INC
- **DATE OF NAME CHANGE:** 20010802

![cmegroup_2cxrgb1.jpg](cmegroup_2cxrgb1.jpg)

September 25, 2025

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Crypto Assets

100 F Street, N.E.

Washington, DC 20549

ATTN: David Irving

&nbsp;&nbsp;&nbsp;&nbsp;Mark Brunhofer

Filed Via EDGAR as Correspondence

&nbsp;&nbsp;&nbsp;&nbsp;RE: &nbsp;&nbsp;&nbsp;&nbsp;CME Group, Inc.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 10-K for Fiscal Year Ended December 31, 2024

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 8-K Filed July 23, 2025

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;File No. 001-31553

Dear David Irving and Mark Brunhofer:

This letter sets forth the responses of CME Group, Inc. ("CME", "the Company", "we", "our" or "us") to the comments of the Staff of the U.S. Securities and Exchange Commission (the "Staff") from comment letter dated September 12, 2025 with respect to the above referenced Form 10-K and Form 8-K. For your convenience, we have duplicated the original comments of the Staff as set forth in the comment letter below in italics in providing our responses to each of the Staff's comments.

*<u>Form 10-K for Fiscal Year Ended December 31, 2024</u>*

*<u>Notes to Consolidated Financial Statements</u>*

*<u>Note 18. Segment Reporting, page 82</u>*

*1.Please represent to us that you will revise future filings to include the geographic disclosures under ASC 280-10-50-41. Otherwise, tell us why they are not required.*

------

**CME Response:** 

We will provide the geographic disclosures in our future annual filings, as required by ASC 280-10-50-41. The following is an illustration of the proposed disclosure to be included within footnote 18, Segment Reporting, in our Form 10-K.

Material revenue and long-lived assets are defined as those which represent 10% or more of total revenues and long lived assets. Revenue and long lived assets by country for the years ended December 31, 2025, 2024 and 2023 and as of December 31, 2025 and 2024 are set forth in the table below:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Revenues** <sup>(b)</sup> | **Revenues** <sup>(b)</sup> | **Revenues** <sup>(b)</sup> | **Long-lived Assets** <sup>(c)</sup> | **Long-lived Assets** <sup>(c)</sup> |
|<br>***(in millions)*** | **2025** | **2024** | **2023** | **2025** | **2024** |
| United States | $xxx | $xxx | $xxx | $xxx | $xxx |
| United Kingdom <sup>(a)</sup> | xxx | xxx | xxx | xxx | xxx |
| Other foreign countries | xxx | xxx | xxx | xxx | xxx |
| Totals | $xxx | $xxx | $xxx | $xxx | $xxx |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(a)</sup> United Kingdom includes Great Britain and Northern Ireland.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(b)</sup> Revenues are classified based upon the location of the customer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(c)</sup> Long-lived assets represent property, plant and equipment, indefinite-lived intangible assets, amortizable intangible assets, and other investments included in other assets. See Note 5 for further information on property. See Note 6 for further information on goodwill and other intangible assets. See Note 17 for further information on investments included in other assets. These assets are reported in the country where they are primarily used.

*2.You reference Adjusted Operating Income and state that you recorded all-time record Adjusted Operating Income in the second quarter of 2025. We note that you do not quantify Adjusted Operating Income or include a reconciliation from a GAAP measure to this non-GAAP measure. Please either remove reference to this non-GAAP measure in future releases furnished on Forms 8-K, or advise otherwise as to why it is a meaningful and useful measure and include all of the disclosure requirements of Item 10(e) of Regulation S-K.*

**CME Response:** 

In future filings, the Company will include all applicable disclosure requirements of Item 10(e) of Regulation S-K for non-GAAP measures used. We believe that the presentation of non-GAAP Operating Income provides important supplemental information to management and investors about financial and business trends relating to the company's financial condition and results of operations. We propose to include the following table within our future releases on Form 8-K to quantify and provide a reconciliation for GAAP to non-GAAP Operating Income.

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **CME Group Inc. and Subsidiaries** | **CME Group Inc. and Subsidiaries** | **CME Group Inc. and Subsidiaries** | **CME Group Inc. and Subsidiaries** | **CME Group Inc. and Subsidiaries** |
| **Adjusted Revenue, Operating Expense and Operating Income Reconciliation** | **Adjusted Revenue, Operating Expense and Operating Income Reconciliation** | **Adjusted Revenue, Operating Expense and Operating Income Reconciliation** | **Adjusted Revenue, Operating Expense and Operating Income Reconciliation** | **Adjusted Revenue, Operating Expense and Operating Income Reconciliation** |
| (dollars in millions, except per share amounts; shares in thousands) | (dollars in millions, except per share amounts; shares in thousands) | (dollars in millions, except per share amounts; shares in thousands) | (dollars in millions, except per share amounts; shares in thousands) | (dollars in millions, except per share amounts; shares in thousands) |
|  | **Quarter Ended** <br>**September 30,** | **Quarter Ended** <br>**September 30,** | **Nine Months Ended** <br>**September 30,**  | **Nine Months Ended** <br>**September 30,**  |
|  | **2025** | **2024** | **2025** | **2024** |
| **Total Revenues** | $&nbsp;&nbsp;&nbsp;&nbsp;XXX | $&nbsp;&nbsp;&nbsp;&nbsp;XXX | $&nbsp;&nbsp;&nbsp;&nbsp;XXX | $&nbsp;&nbsp;&nbsp;&nbsp;XXX |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Real estate-related costs (credits) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | XXX | XXX | XXX |
| **Adjusted Revenues** | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX |
| **Expenses** | XXX | XXX | XXX | XXX |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Restructuring and severance | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred compensation<sup>(1)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of purchased intangibles | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Strategic transaction-related costs | XXX | XXX | XXX | XXX |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Real estate-related costs (credits) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Foreign exchange transactions (gains) losses | XXX | XXX | XXX | XXX |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unrealized and realized (gains) losses on assets | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Litigation matters or settlements | XXX | XXX | XXX | XXX |
| **Adjusted Operating Expenses** | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX |
| **Operating Income** | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX |
| **Adjusted Operating Income** | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX |
| 1. Includes $X.X million and $X.X million for a change in our non-qualified deferred compensation liability in the third quarter and first nine months of 2025. This impact does not affect net income, because the compensation and benefits change has an equal and offsetting change in investment income. | 1. Includes $X.X million and $X.X million for a change in our non-qualified deferred compensation liability in the third quarter and first nine months of 2025. This impact does not affect net income, because the compensation and benefits change has an equal and offsetting change in investment income. | 1. Includes $X.X million and $X.X million for a change in our non-qualified deferred compensation liability in the third quarter and first nine months of 2025. This impact does not affect net income, because the compensation and benefits change has an equal and offsetting change in investment income. | 1. Includes $X.X million and $X.X million for a change in our non-qualified deferred compensation liability in the third quarter and first nine months of 2025. This impact does not affect net income, because the compensation and benefits change has an equal and offsetting change in investment income. | 1. Includes $X.X million and $X.X million for a change in our non-qualified deferred compensation liability in the third quarter and first nine months of 2025. This impact does not affect net income, because the compensation and benefits change has an equal and offsetting change in investment income. |

---

We will also continue to include the reconciliation for GAAP to non-GAAP Net Income, Net Income Attributable to CME Group and Diluted EPS as shown in the following table.

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **CME Group Inc. and Subsidiaries** | **CME Group Inc. and Subsidiaries** | **CME Group Inc. and Subsidiaries** | **CME Group Inc. and Subsidiaries** | **CME Group Inc. and Subsidiaries** |
| **Adjusted Net Income, Net Income Attributable to CME Group and Diluted EPS Reconciliation** | **Adjusted Net Income, Net Income Attributable to CME Group and Diluted EPS Reconciliation** | **Adjusted Net Income, Net Income Attributable to CME Group and Diluted EPS Reconciliation** | **Adjusted Net Income, Net Income Attributable to CME Group and Diluted EPS Reconciliation** | **Adjusted Net Income, Net Income Attributable to CME Group and Diluted EPS Reconciliation** |
| (dollars in millions, except per share amounts; shares in thousands) | (dollars in millions, except per share amounts; shares in thousands) | (dollars in millions, except per share amounts; shares in thousands) | (dollars in millions, except per share amounts; shares in thousands) | (dollars in millions, except per share amounts; shares in thousands) |
|  | **Quarter Ended** <br>**September 30,** | **Quarter Ended** <br>**September 30,** | **Nine Months Ended** <br>**September 30,**  | **Nine Months Ended** <br>**September 30,**  |
|  | **2025** | **2024** | **2025** | **2024** |
| **Net Income** | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;XXX | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;XXX | $&nbsp;&nbsp;&nbsp;&nbsp; XXX | $&nbsp;&nbsp;&nbsp;&nbsp; XXX |
| Restructuring and severance | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | XXX | XXX |
| Amortization of purchased intangibles<sup>(1)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | XXX | XXX |
| Strategic transaction-related costs (credits) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | XXX | XXX |
| Real estate-related costs (credits) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | XXX | XXX |
| Foreign exchange transaction (gains) losses | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | XXX | XXX |
| Unrealized and realized (gains) losses on investments | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | XXX | XXX |
| Unrealized and realized (gains) losses on assets | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | XXX | XXX |
| Litigation matters or settlements | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | XXX | XXX |
| Income tax effect related to above | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | XXX | XXX |
| Other income tax items | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | XXX | XXX |
| **Adjusted Net Income** | $XXX | $XXX | $XXX | $XXX |
| **Adjusted Net Income Attributable to Common Shareholders of CME Group** | $XXX | $XXX | $XXX | $XXX |
| **Earnings per Share Attributable to Common Shareholders of CME Group:** | **Earnings per Share Attributable to Common Shareholders of CME Group:** | **Earnings per Share Attributable to Common Shareholders of CME Group:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Basic | $&nbsp;&nbsp;&nbsp;&nbsp;XXX | $&nbsp;&nbsp;&nbsp;&nbsp;XXX | $&nbsp;&nbsp;&nbsp;&nbsp;XXX | $&nbsp;&nbsp;&nbsp;&nbsp;XXX |
| &nbsp;&nbsp;&nbsp;&nbsp; Diluted | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX |
| **Adjusted Earnings per Share Attributable to Common Shareholders of CME Group:** | **Adjusted Earnings per Share Attributable to Common Shareholders of CME Group:** | **Adjusted Earnings per Share Attributable to Common Shareholders of CME Group:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Basic | $&nbsp;&nbsp;&nbsp;&nbsp;XXX | $&nbsp;&nbsp;&nbsp;&nbsp;XXX | $&nbsp;&nbsp;&nbsp;&nbsp;XXX | $&nbsp;&nbsp;&nbsp;&nbsp;XXX |
| &nbsp;&nbsp;&nbsp;&nbsp; Diluted | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX |
| **Weighted Average Number of Common Shares:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Basic | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX |
| &nbsp;&nbsp;&nbsp;&nbsp; Diluted | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX |
| &nbsp;&nbsp;&nbsp;&nbsp;Preferred shares<sup>(2)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XXX |
| 1. Includes $X.X million and $X.X million of amortization of purchased intangibles (net of tax) at OSTTRA and $X.X million and $X.X million of amortization of purchased intangibles at S&P Dow Jones Indices LLC in the third quarter and first nine months of 2025. This is reported in Equity in net earnings of unconsolidated subsidiaries on the Consolidated Statements of Income. | 1. Includes $X.X million and $X.X million of amortization of purchased intangibles (net of tax) at OSTTRA and $X.X million and $X.X million of amortization of purchased intangibles at S&P Dow Jones Indices LLC in the third quarter and first nine months of 2025. This is reported in Equity in net earnings of unconsolidated subsidiaries on the Consolidated Statements of Income. | 1. Includes $X.X million and $X.X million of amortization of purchased intangibles (net of tax) at OSTTRA and $X.X million and $X.X million of amortization of purchased intangibles at S&P Dow Jones Indices LLC in the third quarter and first nine months of 2025. This is reported in Equity in net earnings of unconsolidated subsidiaries on the Consolidated Statements of Income. | 1. Includes $X.X million and $X.X million of amortization of purchased intangibles (net of tax) at OSTTRA and $X.X million and $X.X million of amortization of purchased intangibles at S&P Dow Jones Indices LLC in the third quarter and first nine months of 2025. This is reported in Equity in net earnings of unconsolidated subsidiaries on the Consolidated Statements of Income. | 1. Includes $X.X million and $X.X million of amortization of purchased intangibles (net of tax) at OSTTRA and $X.X million and $X.X million of amortization of purchased intangibles at S&P Dow Jones Indices LLC in the third quarter and first nine months of 2025. This is reported in Equity in net earnings of unconsolidated subsidiaries on the Consolidated Statements of Income. |
| 2. Preferred shares have similar rights as common shares without voting rights. | 2. Preferred shares have similar rights as common shares without voting rights. | 2. Preferred shares have similar rights as common shares without voting rights. | 2. Preferred shares have similar rights as common shares without voting rights. | 2. Preferred shares have similar rights as common shares without voting rights. |

---

------

In addition, the Company acknowledges:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Company is responsible for the adequacy and accuracy of the disclosures in the filing;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Staff comments or changes to disclosures in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws in the United States.

Please do not hesitate to call me at 312-930-1309 if you have any questions or would like any additional information regarding this matter.

Sincerely,

/s/ Lynne Fitzpatrick

_______________________________________

Lynne Fitzpatrick

*President & Chief Financial Officer*

CME Group Inc.

<br>